Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JSKN 016

Next Previous
Drug Profile

JSKN 016

Alternative Names: JSKN-016; JSKN-016-HC

Latest Information Update: 10 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alphamab Oncology
  • Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Triple negative breast cancer
  • Phase II Non-small cell lung cancer
  • Phase I/II HER2 negative breast cancer
  • Phase I Solid tumours

Most Recent Events

  • 02 Apr 2026 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease) in China (IV) (NCT06868732)
  • 31 Mar 2026 Shanghai Pulmonary Hospital plans a phase II trial for Non-small cell lung cancer (Combination therapy, Neoadjuvant therapy, First line therapy) in China, in March 2026 (NCT07493980)
  • 17 Mar 2026 Phase-III clinical trials in Triple-negative-breast-cancer (Inoperable/Unresectable, Late-stage disease, Recurrent, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT07533123)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top